

Table. Baseline Characteristics of Patient Survey Respondents From a Phase 3 Study of Diazepam Nasal Spray (n=66)

Demographics	5 mg Dose (n=1)	10 mg Dose (n=18)	15 mg Dose (n=20)	20 mg Dose (n=27)	Total (n=66)
Sex					
Male	0	11 (61.1)	9 (45.0)	15 (55.6)	35 (53.0)
Female	1 (100)	7 (38.9)	11 (55.0)	12 (44.4)	31 (47.0)
Race					
White	1 (100)	12 (66.7)	16 (80.0)	22 (81.5)	51 (77.3)
Black or African American	0	2 (11.1)	2 (10.0)	2 (7.4)	6 (9.1)
Asian	0	2 (11.1)	0	0	2 (3.0)
Native Hawaiian or Other Pacific Islander	0	0	1 (5.0)	2 (7.4)	3 (4.5)
Other	0	2 (11.1)	1 (5.0)	1 (3.7)	4 (6.1)
Age, years					
Median	26.0	11.5	24.0	35.0	24.5
Min, max	26, 26	7, 65	12, 54	11, 59	7, 65
Duration of exposure					
<6 months	0	1 (5.6)	0	0	1 (1.5)
6 to <12 months	1 (100.0)	7 (38.9)	2 (10.0)	3 (11.1)	13 (19.7)
≥12 months	0	10 (55.6)	18 (90.0)	24 (88.9)	52 (78.8)

Max, maximum; min, minimum.